These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33075795)

  • 21. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.
    Zatelli MC; Tagliati F; Taylor JE; Rossi R; Culler MD; degli Uberti EC
    J Clin Endocrinol Metab; 2001 May; 86(5):2161-9. PubMed ID: 11344221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-proliferative effects of a novel isoflavone derivative in medullary thyroid carcinoma: an in vitro study.
    Greenman Y; Grafi-Cohen M; Sharon O; Knoll E; Kohen F; Stern N; Somjen D
    J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):256-61. PubMed ID: 22776298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.
    Zatelli MC; Tagliati F; Piccin D; Taylor JE; Culler MD; Bondanelli M; degli Uberti EC
    Biochem Biophys Res Commun; 2002 Oct; 297(4):828-34. PubMed ID: 12359227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells.
    Hong SK; Starenki D; Johnson OT; Gestwicki JE; Park JI
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-proliferative and anti-invasive effects of ferulic acid in TT medullary thyroid cancer cells interacting with URG4/URGCP.
    Dodurga Y; Eroğlu C; Seçme M; Elmas L; Avcı ÇB; Şatıroğlu-Tufan NL
    Tumour Biol; 2016 Feb; 37(2):1933-40. PubMed ID: 26334619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT.
    Fuchs R; Schwach G; Stracke A; Meier-Allard N; Absenger M; Ingolic E; Haas HS; Pfragner R; Sadjak A
    Anticancer Res; 2015 Jan; 35(1):31-38. PubMed ID: 25550532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.
    Tomoda C; Moatamed F; Naeim F; Hershman JM; Sugawara M
    Exp Biol Med (Maywood); 2008 Nov; 233(11):1433-40. PubMed ID: 18791128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
    Díez JJ; Iglesias P
    J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
    Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
    Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EF24 (a Curcumin Analog) and ZSTK474 Emphasize the Effect of Cabozantinib in Medullary Thyroid Cancer.
    Bertazza L; Sensi F; Cavedon E; Watutantrige-Fernando S; Censi S; Manso J; Vianello F; Casal Ide E; Iacobone M; Pezzani R; Mian C; Barollo S
    Endocrinology; 2018 Jun; 159(6):2348-2360. PubMed ID: 29688429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
    Faggiano A; Ramundo V; Dicitore A; Castiglioni S; Borghi MO; Severino R; Ferolla P; Crinò L; Abbruzzese A; Sperlongano P; Caraglia M; Ferone D; Hofland L; Colao A; Vitale G
    J Cell Mol Med; 2012 Jul; 16(7):1563-72. PubMed ID: 21883896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
    Samadi AK; Bazzill J; Zhang X; Gallagher R; Zhang H; Gollapudi R; Kindscher K; Timmermann B; Cohen MS
    Surgery; 2012 Dec; 152(6):1238-47. PubMed ID: 23158190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leflunomide suppresses growth in human medullary thyroid cancer cells.
    Alhefdhi A; Burke JF; Redlich A; Kunnimalaiyaan M; Chen H
    J Surg Res; 2013 Nov; 185(1):212-6. PubMed ID: 23816245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medullary thyroid carcinoma and hormones.
    Cohen R; Quidville V; Bihan H
    Ann Med Interne (Paris); 2003 Mar; 154(2):109-16. PubMed ID: 12746649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.
    Vitale G; Dicitore A; Pepe D; Gentilini D; Grassi ES; Borghi MO; Gelmini G; Cantone MC; Gaudenzi G; Misso G; Di Blasio AM; Hofland LJ; Caraglia M; Persani L
    Mol Oncol; 2017 Aug; 11(8):1007-1022. PubMed ID: 28453190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.
    Alqahtani T; Kumarasamy VM; Huczyński A; Sun D
    Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells.
    Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC
    Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
    Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
    J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor activity of motesanib in a medullary thyroid cancer model.
    Coxon A; Bready J; Kaufman S; Estrada J; Osgood T; Canon J; Wang L; Radinsky R; Kendall R; Hughes P; Polverino A
    J Endocrinol Invest; 2012 Feb; 35(2):181-90. PubMed ID: 21422803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.